Hyperuricemia Resistant to a Xanthine Oxidase Inhibitor, Topiroxostat: a Case Report

被引：0
|
作者：
Takahide Kimura
Seiki Yamada
Masayuki Tanemoto
机构：
[1] International University of Health and Welfare,Division of Nephrology, Department of Internal Medicine
来源：
SN Comprehensive Clinical Medicine | / 4卷 / 1期
关键词：
Chronic kidney disease; Gout; Hyperuricemia; Xanthine oxidase;
D O I：
10.1007/s42399-021-01081-1
中图分类号：
学科分类号：
摘要：
Hyperuricemia is a common complication of chronic kidney disease. Gout is a clinical symptom of hyperuricemia, and lowering serum uric acid concentration (sUA) is recommended to prevent its recurrence. Febuxostat and topiroxostat are sUA-lowering agents, which are presumed to act on the same site of xanthine oxidase (XO), the rate-limiting enzyme for urate production. We present a case of gout where febuxostat but not topiroxostat lowered sUA. The different efficacy between them indicates that XO inhibitors are not interchangeable even among those acting on the same site of XO.
引用
收藏
相关论文
共 50 条
  • [31] Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia
    Omizo, Hiroki
    Tamura, Yoshifuru
    Morimoto, Chikayuki
    Ueno, Masaki
    Hayama, Yuto
    Kuribayashi-Okuma, Emiko
    Uchida, Shunya
    Shibata, Shigeru
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [32] Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia
    Hiroki Omizo
    Yoshifuru Tamura
    Chikayuki Morimoto
    Masaki Ueno
    Yuto Hayama
    Emiko Kuribayashi-Okuma
    Shunya Uchida
    Shigeru Shibata
    Scientific Reports, 10
  • [33] Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion
    Hiroyuki Terawaki
    Hokuto Hoshi
    Junichiro James Kazama
    Clinical and Experimental Nephrology, 2017, 21 : 356 - 357
  • [34] Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplanin
    Zhang, Ying
    Fukusumi, Yoshiyasu
    Kayaba, Mutsumi
    Nakamura, Takashi
    Sakamoto, Ryusuke
    Ashizawa, Naoki
    Kawachi, Hiroshi
    NEFROLOGIA, 2021, 41 (05): : 539 - 547
  • [35] Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury
    Kamijo-Ikemori, Atsuko
    Sugaya, Takeshi
    Hibi, Chihiro
    Nakamura, Takashi
    Murase, Takayo
    Oikawa, Tsuyoshi
    Hoshino, Seiko
    Hisamichi, Mikako
    Hirata, Kazuaki
    Kimura, Kenjiro
    Shibagaki, Yugo
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2016, 310 (11) : F1366 - F1376
  • [36] Efficacy and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase for the Treatment of Hyperuricemia in Kidney Transplant Recipients
    Tojimbara, T.
    Nakajima, I.
    Yashima, J.
    Fuchinoue, S.
    Teraoka, S.
    TRANSPLANTATION PROCEEDINGS, 2014, 46 (02) : 511 - 513
  • [37] Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion
    Terawaki, Hiroyuki
    Hoshi, Hokuto
    Kazama, Junichiro James
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2017, 21 (02) : 356 - 357
  • [38] Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia
    Komoriya, K
    Hoshide, S
    Takeda, K
    Kobayashi, H
    Kubo, J
    Tsuchimoto, M
    Nakachi, T
    Yamanaka, H
    Kamatani, N
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9): : 1119 - 1122
  • [39] POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING AND SIMULATION FOR TIGULIXOSTAT, A NOVEL XANTHINE OXIDASE INHIBITOR FOR THE TREATMENT OF GOUT WITH HYPERURICEMIA
    Denney, W.
    Lee, M.
    Lee, N.
    Jun, H.
    Seo, J.
    Lee, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S69 - S69
  • [40] Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout
    Yang, Xinye
    Li, Yong
    Pan, Shengqiang
    Ma, Facheng
    Chen, Hong
    Deng, Jinhui
    Yue, Jie
    Gong, Qijie
    Zheng, Mi
    Zeng, Ying
    Li, Jing
    Zhang, Yingjun
    Wang, Xiaojun
    Zhang, Xiaojin
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (16) : 14668 - 14691
12345